Skip to content

 

ACT UP/NY, Out-FM (the progressive LGBTQ program on WBAI, 99.5 FM), and the Manhattan LGBT Center
are co-sponsoring a Daylong Conference:

30 Years of ACT UP: Hidden Histories and Voices, Lessons Learned


Sunday, June 18 - 11 AM - 6 PM
The LGBT Community Center, 208 W. 13th St., Manhattan

This full-day conference will focus on some of the often-ignored campaigns and victories throughout three decades of life-saving direct actions to end AIDS by ACT UP/NY and its coalition allies. By attending plenary (general) and breakout sessions, attendees will hear from activists, engage in small group discussions, and view videos highlighting campaigns that began years ago, but now continue in new ways changing the terrain in the battle against HIV/AIDS!

For more information, email This email address is being protected from spambots. You need JavaScript enabled to view it.

Registration details coming soon.

ACT UP 30th Anniversary Action
ACT UP 30th Anniversary Action
30 YEARS OF ACTING UP TO END AIDS envisions a country and a world free of AIDS in the next generation. Our demands fall under the following broad issue themes:

-Ending the AIDS pandemic
-Defending and expanding access to health care and coverage
-Fighting for affordable HIV and hepatitis C drug prices and access
-Finding a cure for HIV/AIDS
-Defending the human rights of all oppressed communities in ending the AIDS crisis
-Ending HIV criminalization laws

At the 30 YEARS OF ACTING UP TO END AIDS action we will commit ourselves to resisting the current political environment based on fear-mongering, bigotry, and the disenfranchisement of vulnerable people, including people living with HIV and hepatitis C. We are still united in anger against policies that undermine people’s right to health care, and we embrace the new tidal wave of resistance and activism to re-commit to an end to AIDS in this generation!

What: 30 YEARS OF ACTING UP TO END AIDS: ACT UP 30th Anniversary March and Rally
When: Thursday, March 30, 2017 -- 4 to 7PM
Starting point at 4PM: AIDS Memorial, 200-218 West 12th Street, (near 7th Ave)
New York City
March route: West Village to Union Square
Rally location at 5PM: Union Square, open plaza on East 17th Street

Co-Supporters Include:

Lambda Legal
Housing Works
GMHC
Antiviolence Project
Make the Road NY
The Lesbian, Gay, Bisexual & Transgender Community Center
VOCAL NY
TAG: Treatment Action Group
Health GAP: Global Access Project
Latino Commision on AIDS
Metro New York Health Care For All
AREA: The American Run for the End of AIDS
Rise and Resist
Bailey House

#RocheGreedKills

7th February 2017

Today we stand together as women living with cancer, families of people with cancer, activists, scientists, researchers and health professionals from across the world. Together we demand that no woman go without it lifesaving breast cancer treatment because it is too expensive.

 (Click photo for hi-res image)

We demand justice for Tobeka Daki.

A fearless activist from South Africa who was living with HER2+ breast cancer since 2013. Despite being a good candidate for trastuzumab, Tobeka was never able to access the treatment due to its high cost.

 On 14 November 2016 she died in her home.

 We do not know whether trastuzumab would have saved Tobeka’s life – trastuzumab doesn’t always work. We do know, however, that Tobeka was never given a chance. Even though she was dying and the medicine existed, she was never given an opportunity to try it.

The price of trastuzumab varies in countries across the world. These prices aren’t always public. They are agreed behind closed doors.

 In South Africa the annual price in the private sector is around US$ 38,365. The few public facilities which can access trastuzumab do so at a lower price of around US$ 15,735 per year. Both out of reach of most.

  • In Brazil it costs US$ 17,562.
  • In Malaysia it costs US$ 17,929.
  • In France it costs US$ 30,595.
  • In India it costs US$ 10,938*.

 But, health economists have shown that a year’s worth of trastuzumab can be produced and sold for only US$ 240. Drastically less. This estimated price even includes a 50% increase above the cost of production for profit.

Meanwhile Roche are posting fat profits.

Roche CEO Severin Schwan
Roche CEO Severin Schwan

In 2015 Roche made US$ 8.9-billion profit. In the same year CEO Severin Schwan earned US$ 12-million. It seems highly plausible that Roche could cut the price of trastuzumab dramatically and still be very profitable.

 Instead Roche maintains it’s high prices in any way possible. Roche holds multiple evergreened patents on trastuzumab in certain countries across the world. In South Africa, for example, multiple patents extend their monopoly until 2033.

 In countries where the patents have ended or do not exist, Roche is using other means to block potentially more affordable biosimilar versions coming to market. In India Roche have initiated a court challenge against the Indian regulatory body for its decision to approve Mylan’s version as a biosimilar product.

 In Brazil and Argentina, Roche is one of the pharmaceutical companies litigating against those governments for their attempts to use legal international safeguards to protect public health.

 For countries like the UK and the US, Roche are trying to charge a price for T-DM1, the drug breast cancer patients need once trastuzumab fails, that is so high even they cannot afford it.

 For too long Roche has been allowed to charge exorbitant prices for these lifesaving treatments.

Tobeka had one life. Her two children had one mother. We had the means to give her a chance at survival and we failed her – as we will continue to fail other women.

 What is most disturbing is the unconcerned attitude and the lack of basic humanity shown by people at Roche. It is not as if they are unaware that many people can’t access trastuzumab because of its high price.

Manfred Heinzer (Roche South Africa General Manager)
Manfred Heinzer (Roche South Africa General Manager)

Shame on you Manfred Heinzer (Roche South Africa General Manager) for not having done more since hearing about Tobeka’s plight six months before her death.

 Shame on you Severin Schwan (Roche CEO) for insisting on fat profits while you could save lives by trimming your profits.

 You could have given Tobeka a chance, but instead you turned your back on her.

Don’t turn your back on all the other women across the world.

WE DEMAND THAT ROCHE:

 - Drop the price of trastuzumab and T-DM1 so that all women living with HER2+ breast cancer who need

All Alumni are invited to this 30th Anniversary of ACT UP NY. We will assemble for #3DecadesofDetermination - a celebration of ACTUP and Jim Eigo.

Wed, March 22, 2017 Celebrate Three Decades of Determination with the present floor of ACTUP, our alumni, allies and friends. tickets are $0 to $300 for attendees. Visit Eventbrite or or bring your donation to the door Cash or Credit Card.
6:00 PM – 9:00 PM EDT Add to Calendar

Keith D. Cylar House
747 E 9th St
New York, NY 10009 View Map

Silence Death

Description

Celebrate Three Decades of Determination with the present floor of ACTUP, our alumni, allies and friends.

Tickets to Hamilton and Anastasia, When We Rise signed script, United in Anger DVDs, How to Survive a Plague books.

Recent and remote ACTUP video and imagery

Food, Drink, ACTUP comrades!

Guests of Honor:

Gerri Wells -- Eric Sawyer -- Andy Velez

Original ACTUP members, who answered that first call to action by meeting immediately : Inspiring an entire generation in their wake.

Come help them celebrate the work and retirement of Jim Eigo:

Founding member of the Treatment and Data committee of ACTUP which brought about fundamental changes in AIDS drug research and regulation -- inserting real community input into drugtrials, transforming drug availability and ultimately enabling combination therapy.

Jim returned to the floor of ACTUP in 2013, and co-founded the Prevention of HIV Action Group (PHAG), the renascent ACTUP committee which loudly and forcefully demanded embrace ofPrEP, PEP and TAsP for HIV prevention.

He helped to drive the cornerstone of prevention into the Blueprint to End AIDS in New York State.

His vision of DOHMH Sexual Health Clinics as full-service hubs of HIV prevention and care, should help to change the way folks at risk for HIV are approached, tested, and followed-up.

We will also feature the ongoing roll-out of Legacee Kares, an app for homeless and underprivileged youth focused on connecting them to human service and HIV resources. It was developedwith the help of ACTUP’s current Youth and Homelessness working group.

PLUS: Learn a new twist on a classic chant.

ACTUP! FIGHT BACK!! END AIDS!!!

#RocheGreedKills

ACTIVISTS AROUND THE WORLD MARCH #ForTobeka

- Demonstrations held at Roche & pharma associations in South Africa, Malaysia, UK, France, Zambia, Brazil, US
- 108 organisations endorse a letter to Roche

 

</>

Downloadable video for broadcast

Tuesday, 7th February 2017 – Swiss multinational company Roche faced global condemnation today from women living with cancer, families of people with cancer, activists, scientists, researchers and health professionals from across the world. They highlighted the immoral and unconscionable tactics employed by Roche across the developed and developing world. Roche’s greed is preventing women from accessing affordable versions of trastuzumab, an essential medicine used in the treatment of breast cancer.

The global day of action was led by women living with cancer in South Africa who gathered outside Roche’s office in Johannesburg demanding justice for Tobeka Daki – a leading cancer activist from South Africa whose own struggle against cancer ended last year.

“In South Africa today, we launched the Tobeka Daki Campaign for Access to Trastuzumab

in loving memory of a fearless activist who lead our struggle to ensure women could get this medicine,” said Salomé Meyer of the Cancer Alliance in South Africa. “Even as the likelihood of her being able to get trastuzumab diminished, Tobeka’s determination to ensure other women could access the medicine only grew stronger.”

Despite being a good candidate for trastuzumab, Tobeka was never able to access the treatment due to its high cost. In South Africa the annual price charged by Roche in the private sector is around US$ 38,365 (ZAR 516,700). The few public facilities which can access trastuzumab do so at a lower price of around US$ 15,735 (ZAR 211,920) per year. But, health economists have shown that a year’s worth of trastuzumab can be produced and sold for only US$ 240, a price that includes a 50% increase above the cost of production for profit.

Roche maintains its high prices in every way possible. Roche holds multiple evergreened patents on trastuzumab in certain countries across the world. In South Africa, for example, multiple patents extend Roche’s monopoly until 2033. In countries where the patents expired or do not exist, Roche is using other means to block potentially more affordable biosimilar versions coming to market.